Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 18/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23007057 | 0.90 | NT5E (0.57) | NT5E | |
| SCHEMBL27195189 | 0.88 | NT5E (0.59) | NT5E | |
| SCHEMBL30007802 | 0.88 | NT5E (0.47) | NT5E | |
| SCHEMBL30008010 | 0.86 | LMNA (0.52) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL19370225 | 0.83 | LMNA (0.64) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL24452563 | 0.83 | LMNA (0.64) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL23330708 | 0.83 | LMNA (0.64) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL22628718 | 0.83 | LMNA (0.64) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL22215103 | 0.83 | LMNA (0.64) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL24452562 | 0.83 | LMNA (0.64) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4353732-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2022237747-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | 四川海思科制药有限公司 | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368204-A1 | SMALL MOLECULAR CD73 ANTAGONIST AND USE THEREOF | ENTPD5, ENTPD1, ENTPD2 | LMNA 2664/4885ALDH1A1 507/4885TP53 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.